[1]
Fox CB, Kim J, Le LV, et al. Micro/nanofabricated platforms for oral drug delivery cade. J Control Release 2016; 219: 431-44.
[2]
Musther H, Olivares-Morales A, Hatley O, Liu B, Rostami Hodjegan A. Animal versus human oral drug bioavailability: Do they correlate? Eur J Pharm Sci 2014; 57: 280-91.
[3]
Qiu Y, Lee P. In: Qiu Y, Chen Y, Zhang G, Yu L, Mantri R, Eds.
Developing oral solid dosage forms pharmaceutical theory and
practice. 2nd ed. United States: Mica Haley 2017: 519.
[4]
Ramu S, Reddy PCG, Rao DS, Ramakrishna G. Formulation and evaluation of lansoprazole delayed release pellets. Int J Pharm Chem Biol Sci 2015; 5: 860-78.
[5]
Joshi A. A review - Modified release drug delivery syatem and its significance. Curr Res Biol Pharm Sci 2014; 3: 1-6.
[6]
Agrawal S, Joshi K, Gaud R. Formulation development of Multi Unit Particulate System (MUPS) for anti-diabetic drugs. Asian J Pharm Sci 2016; 11: 77-8.
[7]
Wang J, Sun Y, Li B, Fan R, Li B, Yin T. Preparation and evaluation of tamsulosin hydrochloride sustained-release pellets modified by two-layered membrane techniques. Asian J Pharm Sci 2015; 10: 31-9.
[8]
Tirpude R, Puranik P. Rabeprazole sodium delayed-release multiparticulates: Effect of enteric coating layers on product performance. J Adv Pharm Technol Res 2011; 2: 184-91.
[9]
Samal HB, Debata J, Kumar NN, Sneha S, Kumar P. Formulation and evaluation of enteric coated pellets of omeprazole. Int J Drug Dev Res 2012; 4: 326-33.
[10]
Islam S, Khatun F, Bakr A, Mondal I, Haque M, Mahmud A. A review on biodegradable polymers for enteric coating material. Int J Pharm Pharm Res 2016; 6: 142-59.
[11]
Wilson B, Babubhai PP, Sajeev MS, Jenita JL. Sustained release enteric coated tablets of pantoprazole : Formulation, in vitro and in vivo evaluation. Acta Pharm 2013; 63: 131-40.
[12]
De Barros JM, Scherer T, Dimitrios C, Khutoryanskiy VV, Edwards AD. A laminated polymer film formulation for enteric delivery of live vaccine and probiotic bacteria. J Pharm Sci 2014; 103(7): 1-11.
[13]
Raval MK, Ramani RV, Sheth NR. Formulation and evaluation of sustained release enteric-coated pellets of budesonide for intestinal delivery. Int J Pharma Investig 2013; 3: 203-11.
[14]
Tummala S, Satishkimar M, Prakash A. Formulation and characterization of 5-Fluorouracil enteric coated nanoparticles for sustained and localized release in treating colorectal cancer. Saudi Pharm J 2014; 23(3): 308-14.
[15]
Niranjan C, Priya R, Swain S, Kumar G, Charan K, Ghose D. Pharmaceutical significance of Eudragit : A review. Futur J Pharm Sci 2017; 3: 33-45.
[16]
Kanwar N, Kumar R, Sinha VR. Preparation and evaluation of multi-particulate system (pellets) of Prasugrel hydrochloride. Open Pharm Sci 2015; 2: 74-80.
[17]
Muley S, Nandgude T, Poddar S. Extrusion-spheronization a promising pelletization technique: In-depth review. Asian J Pharm Sci 2016; 11: 684-99.
[18]
Yadav N, Verma A. Pharmaceutical pellets: A versatile carrier for oral controlled delivery of drugs. Indian J Pharm Educ Re 2016; 50: 146-60.
[19]
Vervaet C, Baert L, Remon JP. Extrusion-spheronisation a literature review. Int J Pharm 1995; 116: 131-46.
[20]
Ghebre-Sellassie IKA. Pelletization technique. In: Swarbrick J, Ed.
Encyclopedia of pharmaceutical technology. 3rd ed. New York:
Informa health care; 2007: 2651-62.
[21]
Srivastava SMG. Fluid bed technology: Overview and parameters for process selection. Int J Pharm Sci Drug Res 2010; 2: 236-46.
[22]
Pu D, Li B, Xu J, et al. Mesalazine sustained-release pellets, preparation method
thereof and mesalazine sustained-release capsule CN105456223A 2016.
[23]
Chengzhi Y, Yang K, Xiaobao S. Esomeprazole enteric-coated
tablets and preparation method thereof CN105596310A (2016).
[24]
Guangli NA, Kede J, Liyun C, et al. Preparation technology of inhibition tablet used
for treating acute gastric acid secretion CN105616371A (2016).
[25]
Mufeng X, Xuewei SCH, Jinyan L, et al. Preparation method of [R)-
lansoprazole sustained-release capsule CN105663095A (2016).
[26]
Zhou L, Ye F. Production method of enteric-coated kitasamycin
for feed CN101611766A (2009).
[27]
Labao C. Drug for treating inflammatory rheumatic diseases
through combination of Chinese traditional and western medicine
and preparation method for drug CN106511862A 2017.
[28]
Yusheng B, Tao M, Li X, et al. Sustained release capsule of sodium dexlansoprazole
and preparation method thereof CN106668018A (2017).
[29]
Min T, Bao Y, Liu T, et al. Orally disintegrating tablet of [R)-Lansoprazole sodium and
preparation method thereof CN106727381A (2017).
[30]
Zhuqing H. Preparation process of radix aucklandiae extract
enteric coated pellets CN107595917A (2018).
[31]
Martin W, Peter W, Katrin W, Niclas LE. New modified release
pellet formulations for proton pump inhibitors TW200624127A (2006).
[32]
Persson E, Persson T. Solid dosage form comprising proton pump
inhibitor and suspension made thereof US2017/0165248A (2017).
[33]
Pergoran G, Nils OG, Nils OL, Jessica E. Oral
cholestyramine formulation and use US2017/0224720A1 (2017).
[34]
Vamshi KT, Reddy MS. Formulation and evaluation ofenteric coated pellets of rifampicin and isoniazid with improved rifampicin stability. Asian J Pharm Clin Res 2014; 7: 1-3.
[35]
Lecomtea F, Siepmanna J, Waltherb M. Blends of enteric and GIT-insoluble polymers used for film coating: Physicochemical characterization and drug release patterns. J Control Release 2003; 89: 457-71.
[36]
Kilor VA, Sapkal NP, Awari JG, Shewale BD. Development and characterization of enteric-coated immediate-release pellets of aceclofenac by extrusion/spheronization technique using kappa-carrageenan as a pelletizing agent. AAPS PharmSciTech 2010; 11: 336-43.
[37]
Déo SC, Andreazza IF, Possamai JC. Development of mesalazine pellets coated with methacrylic-derived polymer. Braz J Pharm Sci 2011; 47: 103-9.
[38]
Dukic-Ott A, Beer T, Paul J, Baeyens W. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion / spheronisation. Eur J Pharm Biopharm 2008; 70: 302-12.
[39]
Goyanes A, Souto C, Martínez-Pacheco R. Co-processed MCC-Eudragit® excipients for extrusion-spheronization. Eur J Pharm Biopharm 2011; 79: 658-63.
[40]
Goyanes A, Martinez-Pacheco R. New co-processed MCC-based excipient for fast release of low solubility drugs from pellets prepared by extrusion-spheronization. Drug Dev Ind Pharm 2015; 41: 1-7.
[41]
Tho I, Arne S, Kleinebudde P. Pectinic acid, a novel excipient for production of pellets by extrusion / spheronisation : Preliminary studies. Eur J Pharm Biopharm 2002; 54: 95-9.
[42]
Tian L, Zhang Y, Tang X. Sustained-Release pellets prepared by combination of wax matrices and double-layer coatings for extremely water-soluble drugs. Drug Dev Ind Pharm 2008; 34(6): 569-76.
[43]
Kallai N, Luhn O, Dredan J, Kovacs K, Lengyel MAI. Evaluation of drug release from coated pellets based on isomalt, sugar, and microcrystalline cellulose inert cores. AAPS PharmSciTech 2010; 11: 383-91.
[44]
Patel H, Patel K, Tiwari S, Pandey S, Shah S, Gohel M. Quality by Design (QbD) approach for development of co-processed excipient pellets (MOMLETS) by extrusion-spheronization technique. Recent Pat Drug Deliv Formul 2016; 10: 1-15.
86
7
2
3